Trials / Completed
CompletedNCT04680767
A Study of LY3502970 in Healthy Male Participants
Disposition of [¹⁴C]-LY3502970 Following Oral Administration in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 35 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally. |
| DRUG | [¹⁴C]-LY3502970 | Administered orally. |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2021-07-03
- Completion
- 2021-07-03
- First posted
- 2020-12-23
- Last updated
- 2025-07-17
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04680767. Inclusion in this directory is not an endorsement.